Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 122 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Clopidogrel 75 mg Clear all
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PACT (Platelet Activity After Clopidogrel Termination)

NCT00619073
View directory record Official record
Conditions
Blood Platelets, Clopidogrel
Interventions
clopidogrel + aspirin, placebo, Aspirin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

NeuroCognition After Carotid Recanalization

NCT04219774
View directory record Official record
Conditions
Cognition Disorder, Stroke, Occlusion Carotid
Interventions
Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy)
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - I

NCT01815008
View directory record Official record
Conditions
Platelet Aggregation, Platelet Transcriptome, Coronary Artery Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 24, 2026, 3:27 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

NCT06692933
View directory record Official record
Conditions
Interaction
Interventions
Cannabidiol in the form of hemp, Clopidogrel
Drug
Lead sponsor
Washington State University
Other
Eligibility
21 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Platelets in Chronic HIV Infection

NCT02578706
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Clopidogrel, Aspirin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

NCT01789814
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 24, 2026, 3:27 AM EDT
Recruiting Phase 4 Interventional

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

NCT06228456
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Results available

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

NCT01107912
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
prasugrel, clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Jacksonville, Florida • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT04305587
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
PF-07081532, Placebo, Clopidogrel
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

NCT00153062
View directory record Official record
Conditions
Stroke
Interventions
Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
20,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
204
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Sep 24, 2026, 3:27 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 24, 2026, 3:27 AM EDT
Completed No phase listed Observational

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 24, 2026, 3:27 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 3 Interventional

Secondary Prevention of Small Subcortical Strokes Trial

NCT00059306
View directory record Official record
Conditions
Cerebrovascular Accident, Hypertension
Interventions
aspirin, clopidogrel, Target of Blood Pressure, placebo
Drug · Other
Lead sponsor
University of British Columbia
Other
Eligibility
30 Years and older
Enrollment
3,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 4 Interventional

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

NCT01706510
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
Rapid City Regional Hospital, Inc
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

NCT01129427
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Placebo, Pantoprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 24, 2026, 3:27 AM EDT
Terminated Phase 3 Interventional Results available

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Clopidogrel

NCT04671069
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Clopidogrel
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

NCT00751231
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
clopidogrel, PRT060128
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
La Jolla, California • Torrance, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

NCT04484259
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 24, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Drug
Lead sponsor
POZEN
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 24, 2026, 3:27 AM EDT